louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05648162: Acupuncture-tDCS Convergence Rehabilitation Effect on Stroke Patients
Official title: Convergence of Acupuncture and Transcranial Direct Current Stimulation(tDCS) Rehabilitation Effect on Motor Function of Patients of Acute Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke, Acute
Lead sponsor: Pusan National University Yangsan Hospital
Sponsor class: OTHER
First posted: 2022-12-13
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to confirm the convergence effectiveness of on acupuncture of the chinese medicine and the tDCS of the western medicine on motor function for patients with acute stroke compared to the control group.


Eligibility criteria: Inclusion Criteria:

* Those who within 2 weeks or more and 6 months after a stroke diagnosis.
* Those who have a lesion with a cortex or subcortex
* Adults over 19 years old
* Inpatients and outpatients who can mediate for 4 weeks
* Those who can understand and follow the purpose of this study

Exclusion Criteria:

* Those who fall under the exclusion criteria for electrical acupuncture or acupuncture or tDCS
* Those who have a experience about adverse reaction to the existing electrical acupuncture or acupuncture or tDCS
* Those who have major psychiatric diseases such as major depression disorders, schizophrenia, bipolar disorders, and dementia
* A person who judges that it is not appropriate for a researcher to participate in this study

Primary outcomes:
measure: Change of Korean version of the Fugl-Meyer Assessment Scale(K-FMA) score
timeFrame: Baseline and Week 4
measure: Change of brain activity
timeFrame: Baseline and Week 4
Secondary outcomes:
measure: Change of Korean version of Modified Barthel Index(K-MBI) score
timeFrame: Baseline and Week 4
Other outcomes:
Locations:
city: Gyeongsang
country: Korea, Republic of
facility: Pusan national university Yangsan Hospital
state: Yangsan
Study officials:
affiliation: Pusan National University Yangsan Hospital
name: Young-Il Shin, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02638662: Stress Level and the Relationship With IVF Outcomes.
Official title: Does Stress Affect In-Vitro Fertilization (IVF) Outcome?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2015-12-23
Enrollment: 276
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: IVF patients doing IVF for the first time, or doing it for the third or more time doing it for the sole purpose to donate their eggs

Brief summary: The effect of stress on IVF outcomes.

Detailed description: The purpose of this study is to describe the pattern of psychological distress (depression, anxiety and stress) as assessed by both subjective and objective measures throughout the course of IVF treatment and to investigate its impact on IVF outcome.

Eligibility criteria: Inclusion Criteria:

* Healthy women undergoing IVF at CRMI Ages 20-44

Patients will be divided in different groups depending on whether:

1. They are donating oocytes (control group).
2. They are undergoing IVF for the first time.
3. They are undergoing IVF for the third time and have either failed or succeeded the prior time.

Exclusion Criteria:

* Any patients who are not candidates for IVF
* Any women who have any past or current medical condition unrelated to their infertility concurrent to their history of infertility (e.g., gastrointestinal disease)

Primary outcomes:
measure: Biomarkers Cortisol and adrenocorticotropic hormone ACTH.
timeFrame: 28-35 days
Secondary outcomes:
measure: Questionnaires to be completed are Life Orientation Test-R
timeFrame: 28-35 days
measure: Self- Evaluation Questionnaire (STAI)
timeFrame: 28-35 days
measure: FertiQOL International
timeFrame: 28-35 days
measure: Beck Depression Inventory
timeFrame: 28-35 days
measure: Daily Stress Questionnaire
timeFrame: 28-35 days
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Steven Spandorfer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03183362: Comparison of Barbed and Conventional Sutures in Adhesion Formation Following Cesarean Section
Official title: Comparison of Barbed and Conventional Sutures in Adhesion Formation Following Cesarean Section; a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cesarean Section
Keywords: Barbed sutures,Cesarean Section, adhesions
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-06-12
Enrollment: 110
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this randomized controlled trial is to determine whether the use of barbed sutures to close uterine incision at cesarean section is associated with more postoperative adhesions compared with conventional sutures or not.

Detailed description: The aim of this randomized controlled trial is to determine whether the use of barbed sutures to close uterine incision at cesarean section is associated with an increase in the rate of postoperative adhesions compared with conventional sutures or not. Primigravida patients undergoing transverse lower segment cesarean section will be included in the study.Cesarean section incision will be closed with double layers of continuous barbed or conventional sutures.Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.

Eligibility criteria: Inclusion Criteria:

* Primigravida patients undergoing transverse lower segment cesarean section

Exclusion Criteria:

* Previous laparotomies
* Postoperative fever
* Patients with preterm pregnancies or in labor

Primary outcomes:
measure: Adhesions formation rate
timeFrame: Through study completion, an average of 3 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of medicine, Cairo university
Study officials:
affiliation: Cairo University
name: Usama M. Fouda, Prof.
role: STUDY_CHAIR
affiliation: Cairo University
name: Mohamed Zayed, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT02101762: Study to Compare CAUTI Rates Following ERASE CAUTI Tray Non-Silver vs Silver Coated Foley Catheters
Official title: A Clinical Study to Compare the CAUTI Rates Following ERASE CAUTI Tray Non-Silver Coated Foley Catheters Verse Silver Coated Foley Catheters
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Surgery
Intensive Care Units
Keywords: Foley
Catheters
CAUTI
ERASE CAUTI
Lead sponsor: Medline Industries
Sponsor class: INDUSTRY
First posted: 2014-04-02
Enrollment: 756
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects requiring urinary Foley catheters.

Brief summary: The Foley catheter is one component in a catheter insertion procedure that could contribute to a catheter associated urinary tract infection (CAUTI). Improvement in the catheter insertion procedures using the ERASE CAUTI Tray system may help to lower these infection rates.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Received Either silver coated Foley catheter or ERASE CAUTI non-silver coated catheter

Exclusion Criteria:

* UTI present upon current hospital admission
* Burn patients, transplant patients, or immune-compromised patients.

Primary outcomes:
measure: Change in Urinary tract infection rates
timeFrame: 3-9 months based on size of ICU and catheter usage
Secondary outcomes:
measure: Catheter use
timeFrame: Catheter days
measure: Infection Costs
timeFrame: Duration of infection
Other outcomes:
Locations:
Study officials:
affiliation: Medline Industries
name: Ed Drower, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT03486262: Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Official title: Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Cancer and Idiopathic Pulmonary Fibrosis
Keywords: Lung cancer; Idiopathic pulmonary fibrosis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2018-04-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

Brief summary: Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

Detailed description: Primary objective:

Characterize altered molecular pathways in lung cancer in patients with IPF versus lung cancer in non-IPF patients.

Secondary objectives:

Identify specific therapeutic targets Describe a cohort of lung cancers on IPF (clinical / radiological and pathological data) To study the relationship between neoplastic / preneoplastic lesions and pulmonary parenchyma reshaped by fibrosis.

Eligibility criteria: Inclusion Criteria:

* Lung carcinoma
* Idiopathic pulmonary fibrosis

Exclusion Criteria:

- No tumor sample available

Primary outcomes:
measure: Molecular profile of IPF-associated lung carcinomas
timeFrame: 1 month / 8 samples
Secondary outcomes:
measure: Pathological characterization of lung carcinomas
timeFrame: 1 month / 8 samples
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital BICHAT-CLAUDE BERNARD
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Auréie CAZES, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02125162: A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
Official title: A Single-dose, Randomized, 3-period, Crossover Study to Evaluate the Relative Bioavailability of BCX4161 Formulated as a Soft Gelatin Capsule to BCX4161 Formulated as a Hard Gelatin Capsule and the Effect of Food on BCX4161 Pharmacokinetics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hereditary Angioedema
Keywords: BCX4161
BioCryst
hereditary angioedema
relative bioavailability
kallikrein inhibitor
Lead sponsor: BioCryst Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-04-29
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare how the body takes up and then eliminates the study drug BCX4161 when it is taken orally as a hard gelatin capsule and as a soft gelatin capsule. This study will also evaluate whether food has any effect on how the body takes up BCX4161.


Eligibility criteria: Key Inclusion Criteria:

* Written informed consent
* Body mass index 19 to 32 kg/m2 and a weight of at least 50 kg
* Abide by study restrictions
* Attend all study visits
* Acceptable birth control measures

Key Exclusion Criteria:

* Clinically significant medical history, current medical or psychiatric condition, ECG finding, or laboratory/urinalysis abnormality
* Activated partial thromboplastin time or prothrombin time outside of normal laboratory limits
* Pregnant or nursing
* Recent history of alcohol abuse or positive drugs of abuse screen
* Current smokers
* Donation or loss of greater than 400 mL of blood within 3 months

Primary outcomes:
measure: Plasma pharmacokinetics to assess the relative bioavailability of BCX4161 soft gelatin capsules to hard gelatin capsules
timeFrame: Pharmacokinetic parameters AUC0-inf, AUC0-t and Cmax generated after 24 hours of postdose blood sampling
Secondary outcomes:
measure: Safety and tolerability evaluated through assessments of adverse events, laboratory analyses, vital signs, ECGs, and physical examinations
timeFrame: Screening through study completion (approximately 61 days)
measure: Plasma pharmacokinetics to assess the effect of food on BCX4161
timeFrame: Pharmacokinetic parameters AUC0-inf, AUC0-t and Cmax generated after 24 hours of postdose blood sampling
Other outcomes:
Locations:
city: Ruddington
country: United Kingdom
facility: Quotient Clinical Ltd
state: Nottingham
Study officials:
affiliation: Quotient Clinical Ltd
name: Joanne Collier
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03172962: Effect of Strength Training for Chronic Low Back Pain Patients (IRMA20)
Official title: Effect of Strength Training for Chronic Low Back Pain Patients: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Pain
Low Back Pain
Lead sponsor: National Research Centre for the Working Environment, Denmark
Sponsor class: OTHER_GOV
Collaborators: name: University of Valencia
First posted: 2017-06-01
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Low back pain (LBP) is common in the population and has great socioeconomic consequences for societies across Europe and the United States. About a third of working-age adults have frequent LBP, and for about 10% the pain becomes chronic with consequences for work and leisure activities. A Cochrane review from April 2017 concluded that physical exercise is an intervention with few adverse events and positive outcomes on pain and function in adults with chronic pain. However, when scrutinizing the specific studies of the review there are large differences in adherence to the exercise interventions and consequently in the results obtained. Thus, there is a need for simple exercises that the patients can easily adhere to.


Eligibility criteria: Inclusion Criteria:

* Non-specific Chronic low back pain patient (more than 3 months) at the hospital Arnau de Vilanova

Exclusion Criteria:

* Spine surgery
* neurologic or psyquiatric disorders
* Low back traumastism
* Recent participation in a similar training program

Primary outcomes:
measure: Low back pain intensity
timeFrame: change from baseline to 8-week follow-up
measure: Back pain recurrence
timeFrame: 1 to 100 days, beginning from the last day of termination of the 8-week intervention
Secondary outcomes:
measure: Roland-Morris disability
timeFrame: change from baseline to 8-week follow-up
measure: Muscle endurance
timeFrame: change from baseline to 8-week follow-up
measure: Use of analgesics
timeFrame: change from baseline to 8-week follow-up
measure: Handgrip strength
timeFrame: change from baseline to 8-week follow-up
measure: Pain sites
timeFrame: change from baseline to 8-week follow-up
Other outcomes:
Locations:
city: Lliria
country: Spain
facility: Primary care center of Lliria
state: Valencia
Study officials:
affiliation: University of Valencia
name: Joaquin Calatayud, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03468062: The Effect of Dexmedetomidine on Postoperative Quality of Recovery
Official title: The Effect of Preoperative Intravenous Dexmedetomidine on Postoperative Quality of Recovery: Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: The Effect of Dexmedetomidine on Postoperative Quality of Recovery
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2018-03-16
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Dexmedetomidine is a selective a2-agonist and a sedative with anti-inflammatory,analgesic, and antiemetic effects, and its use for procedural sedation during endoscopy or ablation for atrial fibrillation has been increasing. It is also used for sedation in the intensive care unit. Recently, it was reported that dexmedetomidine is often used as an adjuvant for general anesthesia. Sympatholysis of dexmedetomidine can attenuate the increased sympathetic tone after surgery and result in antistress effects. In addition, opioid-sparing and analgesic effects are promoted by the perioperative administration of dexmedetomidine. Although it has been reported that the perioperative administration of dexmedetomidine improves quality of recovery after spinal and ENT surgeries, the outcomes for patients who undergo laparoscopic cholecystectomy remain poorly investigated.

The aims of this study were to evaluate the effects of preoperative dexmedetomidine administration on quality of recovery by using the QoR-40 questionnaire in patients who undergo laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* The patients who undergo elective cholecystectomy
* Adults (20\~75 years old)
* an American Society of Anesthesiologists physical status of I or II

Exclusion Criteria:

* The patients do not provide written informed consent
* The patients have had allergic response to dexmedetomidine.
* The patients have mood disorder or anxiety disorder.
* The patients are not able to express their emotions.
* The pregnant women

Primary outcomes:
measure: Quality of recovery questionnaire
timeFrame: postoperative first day
Secondary outcomes:
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Gil Medical Center, Gachon University College of Medicine
Study officials:
References:
citation: Choi JJ, Kim K, Park HY, Chang YJ, Lee KC, Kim KY, Kwak HJ. CONSORT the effect of a bolus dose of dexmedetomidine on postoperative pain, agitation, and quality of recovery after laparoscopic cholecystectomy. Medicine (Baltimore). 2021 Jan 22;100(3):e24353. doi: 10.1097/MD.0000000000024353.
Clinical trial NCT02950662: (PEEK) Housing Verses Metallic Housing of Ball and Socket Attachment on Retention of Mandibular Overdenture
Official title: Effect of Polyether Ether Ketone (PEEK) Housing Verses Metallic Housing of Ball and Socket Attachment on Retention of Mandibular Implant Retained Overdentures: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Problem With Dentures
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2016-11-01
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the clinical effect of PEEK housing vs. metal housing in terms of retention and patient satisfaction


Eligibility criteria: Inclusion Criteria:

1. Patient should be free from any systemic disease that may interfere with dental implants placement and/or osseointegration e.g. uncontrolled diabetes, hypertension, blood diseases, bone diseases, smoking.etc.
2. Patients have completely edentulous upper and lower arches.
3. Patients have healthy mucosa free from any ulceration, inflammation or infections.
4. All patients are free from neuromuscular and temporomandibular joint disorders.
5. Selected patients have normal maxillo-mandibular relationship (Angle class I ridge classification) with adequate inter-arch space and normal tongue size.

Exclusion Criteria:

1. Patients with limited manual dexterity.
2. Patients with Xerostomia, excessive salivation or pathological mucosal changes (e.g. Lichen planus, Leukoplakia...etc.)
3. Pregnant females.
4. Un co-operative patients.

Primary outcomes:
measure: Retention of implant supported overdenture by using digital force meter device
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05488262: Management in Intensive Care Unit of Life-threatening Keto-Acidosis
Official title: Management in Intensive Care Unit of Life-threatening Keto-Acidosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ketoacidosis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2022-08-04
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in participating departments.

Brief summary: Patients hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in participating departments.

Detailed description: Analysis of patients with International Statistical Classification of Diseases and Related Health Problems coding compatible with inclusion

* Selection of patients eligible for inclusion based on review of medical records (verification of inclusion and non-inclusion criteria)
* Telephone contact and sending of the information letter on participation in the study and research of the patient's non-opposition to his participation and the processing of his data.
* Collection of retrospective data
* Phone call to collect prospective data

Eligibility criteria: Inclusion Criteria:

* Major (age ≥ 18 years old)
* Hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in the participating departments.
* Diagnosis of ketoacidosis judged to be the main cause of the severity of the clinical condition.
* Blood potential hydrogen \< 7.15 and bicarbonates \< 10mmol/L in the first 12 hours of treatment.
* Presenting at least one of the 3 organ failures during hospitalization among:
* Use of extra-renal purification for acute renal failure
* Administration of pressor amines
* Use of mechanical ventilation

Exclusion Criteria:

* Metabolic acidosis primarily of an origin other than ketonic
* Refusal to participate or opposition to the processing of their data
* Patient under guardianship or curators

Primary outcomes:
measure: evaluate the incidence of mortality in intensive care units of patients hospitalized for severe diabetic ketoacidosis.
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bobigny
country: France
facility: Avicenne
city: Colombes
country: France
facility: Louis Mourier
city: Le Kremlin-Bicêtre
country: France
facility: Bicêtre
city: Paris
country: France
facility: Saint-Louis
Study officials:
References: